Found: 17
Select item for more details and to access through your institution.
Development of Pandemic Vaccines: ERVEBO Case Study.
- Published in:
- Vaccines, 2021, v. 9, n. 3, p. 190, doi. 10.3390/vaccines9030190
- By:
- Publication type:
- Article
Applying Mathematical Tools to Accelerate Vaccine Development: Modeling <i>Shigella</i> Immune Dynamics.
- Published in:
- PLoS ONE, 2013, v. 8, n. 4, p. 1, doi. 10.1371/journal.pone.0059465
- By:
- Publication type:
- Article
Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
- Published in:
- PLoS Neglected Tropical Diseases, 2018, v. 12, n. 4, p. 1, doi. 10.1371/journal.pntd.0006376
- By:
- Publication type:
- Article
Applications of nanotechnology for immunology.
- Published in:
- Nature Reviews Immunology, 2013, v. 13, n. 9, p. 701, doi. 10.1038/nri3517
- By:
- Publication type:
- Article
Applications of nanotechnology for immunology.
- Published in:
- Nature Reviews Immunology, 2013, v. 13, n. 8, p. 592, doi. 10.1038/nri3488
- By:
- Publication type:
- Article
Immunology of gut mucosal vaccines.
- Published in:
- Immunological Reviews, 2011, v. 239, n. 1, p. 125, doi. 10.1111/j.1600-065X.2010.00970.x
- By:
- Publication type:
- Article
Immune responses to O-specific polysaccharide (OSP) in North American adults infected with Vibrio cholerae O1 Inaba.
- Published in:
- PLoS Neglected Tropical Diseases, 2019, v. 13, n. 11, p. 1, doi. 10.1371/journal.pntd.0007874
- By:
- Publication type:
- Article
Association Between State Hepatitis A Vaccination Requirements and Hepatitis A Vaccination Rates.
- Published in:
- Journal of the Pediatric Infectious Diseases Society, 2022, v. 11, n. 6, p. 295, doi. 10.1093/jpids/piac013
- By:
- Publication type:
- Article
Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
- Published in:
- Clinical Infectious Diseases, 2016, v. 62, n. 11, p. 1329, doi. 10.1093/cid/ciw145
- By:
- Publication type:
- Article
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
- Published in:
- Clinical Infectious Diseases, 2024, v. 78, n. 4, p. 870, doi. 10.1093/cid/ciad693
- By:
- Publication type:
- Article
Effects of Gamma Irradiation of Human Serum Samples from rVSVΔG-ZEBOV-GP (V920) Ebola Virus Vaccine Recipients on Plaque-Reduction Neutralization Assays.
- Published in:
- American Journal of Tropical Medicine & Hygiene, 2021, v. 104, n. 5, p. 1751, doi. 10.4269/ajtmh.20-1055
- By:
- Publication type:
- Article
Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Gut-homing conventional plasmablasts and CD27<sup>-</sup> plasmablasts elicited after a short time of exposure to an oral live-attenuated Shigella vaccine candidate in humans.
- Published in:
- Frontiers in Immunology, 2014, v. 5, p. 1, doi. 10.3389/fimmu.2014.00374
- By:
- Publication type:
- Article
Gut-homing conventional plasmablasts and CD27- plasmablasts elicited after a short time exposure to an oral live attenuated Shigella vaccine candidate in humans.
- Published in:
- Frontiers in Immunology, 2014, v. 5, p. 1, doi. 10.3389/fimmu.2014.00374
- By:
- Publication type:
- Article
Correction: A clinically parameterized mathematical model of Shigella immunity to inform vaccine design.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
A clinically parameterized mathematical model of Shigella immunity to inform vaccine design.
- Published in:
- PLoS ONE, 2018, v. 13, n. 1, p. 1, doi. 10.1371/journal.pone.0189571
- By:
- Publication type:
- Article